Contact prophylaxis for invasive meningococcal or Hib disease

  • PIC logo
    PIC Endorsed
  • *Approved by CPG Committee, PIC endorsement pending

    See also

    Acute meningococcal disease
    Meningitis and encephalitis 
    Invasive group A streptococcal infections: management of household contacts

    Contact prophylaxis for invasive meningococcal and Haemophilus influenzae type b (Hib) disease involves the treatment of at-risk contacts to eliminate nasopharyngeal carriage, thereby reducing transmission and the risk of secondary cases; it should be given to contacts as soon as possible

    Antimicrobial recommendations may vary according to local antimicrobial susceptibility patterns. Refer to local guidelines

    Neisseria meningitidis

    Requires contact prophylaxis

    Close and prolonged contact within 7 days prior to the onset of symptoms until 24 hours after antibiotic treatment including

    • Household contacts (highest risk group)
    • Childcare contact in same care group (equivalent degree of contact as a household contact)
      • Two full 6-8 hour days
        Or
      • Cumulative 20 hours of contact
    • Intimate contacts (kissing)
    • Healthcare workers who have unprotected close airway exposure and inadequate PPE
    • Passengers sitting immediately adjacent to a case for >8 hours
    Antibiotic

    Ciprofloxacin PO as a single dose

    • <5 years: 30 mg/kg (max 125 mg)
    • 5-12 years: 250 mg
    • ≥12 years: 500 mg

    Ceftriaxone is preferred in pregnancy. Rifampicin is preferred in neonates

    Rifampicin is contraindicated in pregnancy and severe liver disease

    Rifampicin PO BD for 2 days

    • <1 month: 5 mg/kg (<1 month)
    • ≥1 month: 10 mg/kg (max 600 mg)
    • See pharmacological considerations below

    Pregnancy or contraindication to Rifampicin:

    Ceftriaxone IM as a single dose

    • ≥12 years: 250 mg
    • 1 month to 12 years: 125 mg
    Notes
    • Prophylaxis must be given early to both the index case and contacts, especially for N. meningitidis disease, because of the rapidity with which secondary cases may develop
    • The risk of developing meningococcal disease is highest in the 7-10 days after exposure
    • Meningococci are eliminated from the nasopharynx within 24 hours of commencing effective clearance antibiotic therapy
    • Vaccination should be offered to non-immunised contacts of cases with N. meningitidis serogroups A, C, W or Y

    Haemophilus influenzae type b

    Requires contact prophylaxis

    The index patient if they have not been treated with ceftriaxone/cefotaxime

    Close and prolonged contact within 7 days prior to the onset of symptoms until 48 hours after antibiotic treatment including

    • Household contacts if the household contains a vulnerable contact (defined below)
    • Childcare contacts if they have levels of contact of a household contact, and is a vulnerable contact
    • Vulnerable contacts who have shared a hospital room with the index patient
    • Healthcare workers who have unprotected close airway exposure and inadequate PPE

    The definition of a vulnerable contact is

    • an infant <7 months of age (regardless of vaccination status)
    • an immunocompromised or asplenic person of any age (regardless of vaccination status)
    • Inadequately vaccinated per the following age and contact type
      • Childcare: 7 months - 2 years
      • Household and hospital: 7 months - 5 years
    Antibiotic

    Rifampicin PO daily for 4 days

    • <1 month: 10 mg/kg
    • ≥1 month: 20 mg/kg (max 600 mg)
    • See pharmacological considerations below

    Pregnancy or contraindication to Rifampicin

    • Ceftriaxone 50 mg/kg (max 1 g) IM daily for 2 days
    Notes
    Children who are not up to date with Hib should be immunised

    Streptococcus pneumoniae

    • No increased risk to contacts
    • Antibiotic prophylaxis not required

    Rifampicin pharmacological considerations

    • Induces the metabolism of multiple medications
      • Including the oral contraceptive pill (alternative contraception should be instituted), anticonvulsants, warfarin and chloramphenicol
      • A drug interaction check should be completed
      • Rifampicin should not be used if there is hepatic impairment
    • Preferred in infants, although ciprofloxacin is safe and effective
    • Colours body fluids red, for example urine, saliva, tears (soft contact lenses may be damaged), sweat

    *Last updated April 2026